Navigation Links
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Date:4/21/2008

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum's license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006.

SMRX11 is an engineered plasminogen activating hybrid protein produced by recombinant DNA technology. The hybrid protein activates plasminogen only in the presence of a blood clot. In the absence of the blood clot protein, Fibrin, SMRX11 displays no plasminogen activation. This unique product therefore potentially avoids the adverse reactions currently faced by thrombolytics in the market. Such adverse reactions include blood thinning and severe bleeding due to a significant degree of spontaneous plasminogen activation even in the absence of Fibrin. Moreover, SMRX11 protects fibrinogen levels in the blood, while dissolving the clot, and hence further lowering the risk of bleeding.

Nostrum recently successfully completed a proof-of-concept study in a non-human primate thrombolysis model that is expected to bear a close relationship with the future studies in humans. In this study, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow in cynomolgus monkeys following a stable thrombus formation. The animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which Nostrum conducted in a canine thrombolysis model, has confirmed the results observed in the primate study. "We have seen promising results in this primate model. We were clearly able to demonstrate the utility of SMRX11. Further studies will be conducted to show efficacy and safety of the product prior to our planned clinical studies in humans," said Yatindra Prashar, Ph.D., co-founder of Symmetrix. "We are excited about the possibility of treating millions of patients suffering from several cardiovascular conditions including Acute Myocardial Infarction, Ischemic Stroke, Peripheral Arterial Disease and Pulmonary Embolism in a cost efficient manner," said Nirmal Mulye, Ph.D., founder and President of Nostrum.

Nostrum will first pursue the clinical development and launch of SMRX11 in India followed by a worldwide launch. Nostrum's intellectual property as it relates to this technology is protected by patents obtained in the United States, Europe and India.


'/>"/>
SOURCE Nostrum Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):